Downside of finger flicks, upside of abicipar changes

These findings and three other presentations on SRF/IRF, stable CST and oral therapy give new insights into nAMD.

20 milestones ahead in AMD, DME meds

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

Targeting Unmet Needs in nAMD Treatment

A look at longer-acting anti-VEGF agents, sustained-release delivery, gene therapy and novel molecules in development.

The Choroid in AMD: A Critical Point of Failure?

Advancements in imaging and new computational models are improving our understanding of choroidal failure.

The ‘Switch’ and Macular Atrophy in nAMD

New insights into how frequent, long-term anti-VEGF injections and a change in medication impact RPE loss.

Answers to the Three Big Questions of Long-Term Treatment of Wet AMD

Anti-VEGF agents have forced us to choose an agent and regimen, and learn when enough is enough.

Retina Report from ARVO 2016

A closer look at five abstracts on VMT, DME, AMD, OCT and gene therapy.

TAE for Wet AMD: Practical Tips from the Pros

A conversation on the nuances of implementing treat and extend.

Subclinical MNV: Do We Watch or Treat?

Now that we have OCT-A, we can no longer ignore macular neovascularization in non-exudative AMD.

Video Vault

Minimally invasive management of lenticular deposits

Akshay Thomas, MD, MS, of Tennessee Retina demonstrates his surgical technique for removing posterior intraocular lens deposits.